Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

By BiotechDaily International staff writers
Posted on 26 Aug 2014
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).
An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions.

To promote development of low molecular weight ion transporter drugs, investigators at The University of Texas, Austin (USA) sought to show that there was a direct correlation between a change in cellular chloride anion concentration and cytotoxicity for synthetic ion carriers.

To accomplish this goal, the investigators and their colleagues from five other research institutes created two synthetic ion transporters—pyridine diamide-strapped calix[4]pyrroles—that bind to chloride ions.

Results published in the August 11, 2014, online edition of the journal Nature Chemistry revealed that these compounds induced coupled chloride anion and sodium cation transport in both liposomal models and cells, and promoted cell death by increasing intracellular chloride and sodium ion concentrations. Removing either ion from the extracellular media or blocking natural sodium channels prevented this effect.

“We have demonstrated that this mechanism is viable, that this idea that has been around for over two decades is scientifically valid, and that is exciting,” said contributing author Dr. Jonathan L. Sessler, professor of chemistry at the University of Texas, Austin. “We were able to show sodium is really going in, chloride is really going in. There is now, I think, very little ambiguity as to the validity of this two-decades-old hypothesis. We have shown that this mechanism of chloride influx into the cell by a synthetic transporter does indeed trigger apoptosis. This is exciting because it points the way towards a new approach to anticancer drug development.”

The synthetic molecules described in the current study induce programmed cell death in both cancerous and healthy cells. To be of any value in treating cancer, a version of a chloride anion transporter will have to be developed that acts only on cancer cells.

Related Links:

The University of Texas, Austin



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.